Freedom downgraded its rating on aTyr Pharma to “Hold” with a $5 target price

Alignment of a new study with the U.S. regulator reduces uncertainty for aTyr Pharma (ATYR), but funding for the program remains an open question, according to Freedom Broker analysts Ilya Zubkov, Boris Tolkachev and Aydyn Seitzhapbar. They lowered the target price for the shares to $5 and revised the recommendation from “Buy” to “Hold”.

aTyr Pharma is a biotechnology company developing experimental medicines. Its key drug candidate, efzofitimod, is being studied for the treatment of lung diseases. The commercial prospects of the program depend on confirming efficacy in clinical trials and subsequent regulatory approval.

What was agreed with the FDA

The company reported alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a new Phase 3 study of efzofitimod.

It is planned to enroll about 372 patients with pulmonary sarcoidosis and restrictive impairment of lung function—a condition in which the volume of lung expansion is limited. Sarcoidosis is accompanied by the formation of inflammatory lesions that can disrupt organ function.

The primary endpoint will be the change in forced vital capacity of the lungs at 48 weeks. This metric reflects the volume of air a person can forcibly exhale after a deep inhalation. In addition, researchers will assess the impact of the disease on patients’ well-being.

Protocol alignment does not confirm efficacy

Freedom views the agreement with the FDA as an important step to continue the program, but not as proof that the drug works.

The previous EFZO-FIT study did not meet its primary goal—confirming the ability to reduce the dose of steroid medications. The new approach is based on a subsequent analysis of a subgroup of 44 participants.

Selecting a narrower patient category and maintaining stable background therapy should reduce the variability of results. However, the efficacy of efzofitimod still needs to be tested in the new study.

A partner is needed to continue the program

aTyr has begun preparatory activities, but further conduct of the Phase 3 program depends on attracting a strategic partner through a collaboration or licensing agreement. The company stated this condition in its quarterly update.

As of the end of September, cash, investments and restricted cash totaled $50.3 million versus $58.9 million a quarter earlier. Management estimates that resources are sufficient for the current operating plan through the end of 2028. However, this guidance does not mean that a full-scale Phase 3 study is already financed.

The company also completed a workforce reduction of about 60%, to 20 employees. Expected annual savings are about $13 million.

Why Freedom revised its valuation

aTyr’s net loss for the quarter narrowed from $25.7 million to $18.3 million. Research and development expenses declined after the completion of EFZO-FIT, but administrative expenses increased due to restructuring.

In Freedom’s view, the cost savings buy the company time for negotiations but do not eliminate the main risk. The timing of the study launch and the terms of a potential partnership remain uncertain.

Previously, Freedom Broker noted the preparation of a new efzofitimod research program. Now, the decisive event is the signing of an agreement that will provide funding and support for the trials.

In the new valuation, analysts factor in available liquidity net of expected expenses and the development value adjusted for risks. Until there is clarity on a partnership, Freedom maintains a more cautious view on the shares.

Not an individual investment recommendation.